Artwork

Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Using AI and Synthetic Biology to Go Where Antibody Therapies Can’t

57:58
 
Distribuie
 

Manage episode 446655291 series 3551733
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Monoclonal antibodies have been an important addition to the biomedical arsenal, but these therapies have limited ability to target a group of cell surface receptors known as GPCRs. Aikium is developing a new class of therapies known as SeqR proteins that offer an alternative to antibody-based drugs and can bind to intrinsically disordered regions of targeted GPCRs that were previously considered undruggable. Venkatesh Mysore, co-founder and CTO of Aikium, sits down with Amar Drawid to discuss how the company is using AI and synthetic biology to discover SeqR protein therapeutics to treat cancer, auto-immune diseases, and neuro-inflammatory disorders.

  continue reading

20 episoade

Artwork
iconDistribuie
 
Manage episode 446655291 series 3551733
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Monoclonal antibodies have been an important addition to the biomedical arsenal, but these therapies have limited ability to target a group of cell surface receptors known as GPCRs. Aikium is developing a new class of therapies known as SeqR proteins that offer an alternative to antibody-based drugs and can bind to intrinsically disordered regions of targeted GPCRs that were previously considered undruggable. Venkatesh Mysore, co-founder and CTO of Aikium, sits down with Amar Drawid to discuss how the company is using AI and synthetic biology to discover SeqR protein therapeutics to treat cancer, auto-immune diseases, and neuro-inflammatory disorders.

  continue reading

20 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință

Listen to this show while you explore
Play